Evidence map›Paper›PMID 25073113›Full record

ArticleBiochemical and biophysical research communications2014

Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins.

Sheng-Fan Wang, Sung-Pin Tseng, Chia-Hung Yen, Jyh-Yuan Yang, Ching-Han Tsao, Chun-Wei Shen, Kuan-Hsuan Chen, Fu-Tong Liu, Wu-Tse Liu, Yi-Ming Arthur Chen and 1 more

Registry-linked trialOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biochemical and biophysical research communications, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04934111 (A Clinical Trial to Assess the Safety and Immunogenicity of LNP-nCOV saRNA-02, a Self-amplifying Ribonucleic Acid), which is not on this map. Cited by 284 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
284citing papers in PubMed, 9 pooled it
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04934111 phase1unknown statusnot on this mapstarted 2021, after this paper: background citation

A Clinical Trial to Assess the Safety and Immunogenicity of LNP-nCOV saRNA-02, a Self-amplifying Ribonucleic Acid (saRNA) Vaccine, in SARS-CoV-2 Seronegative and Seropositive Uganda Population

TypeinterventionalSponsorMRC/UVRI and LSHTM Uganda Research UnitRan2021 to 2022Enrolled42ConditionsCOVID-19ArmsLNP-nCOV saRNA-02 Vaccine
3 · Its place in the literature

Who cites it

284 citing papers in PubMed, 9 syntheses or guidelines pooled it, 445 citations in OpenAlex.

  1. Convalescent plasma for people with COVID-19: a living systematic review.The Cochrane database of systematic reviews · 2023
    Pooled it
  2. Convalescent plasma for people with COVID-19: a living systematic review.The Cochrane database of systematic reviews · 2023
    Pooled it
  3. Hyperimmune immunoglobulin for people with COVID-19.The Cochrane database of systematic reviews · 2023
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Antibody-dependent enhancement of coronaviruses.International journal of biological sciences · 2025
    Review
  20. Article

224 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 1 country.

Sheng-Fan WangDepartment of Medical Laboratory Science and Biotechnology, Kaohsiung Medical University, Kaohsiung, Taiwan; Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan; Center for Infectious Disease and Cancer Research, Kaohsiung Medical University, Kaohsiung, Taiwan.
Sung-Pin TsengDepartment of Medical Laboratory Science and Biotechnology, Kaohsiung Medical University, Kaohsiung, Taiwan.
Chia-Hung YenGraduate Institute of Natural Products, College of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan.
Jyh-Yuan YangCenter for Research, Diagnostics and Vaccine Development, Centers for Disease Control, Taipei, Taiwan.
Ching-Han TsaoInstitute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.
Chun-Wei ShenOffice of Occupational Safety and Health, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan.
Kuan-Hsuan ChenCenter for Infectious Disease and Cancer Research, Kaohsiung Medical University, Kaohsiung, Taiwan.
Fu-Tong LiuInstitute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.
Wu-Tse LiuDepartment of Biotechnology and Laboratory Science in Medicine, National Yang-Ming University, Taipei, Taiwan.
Yi-Ming Arthur ChenCenter for Infectious Disease and Cancer Research, Kaohsiung Medical University, Kaohsiung, Taiwan; Department of Microbiology, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. Electronic address: arthur@kmu.edu.tw.
Jason C HuangDepartment of Biotechnology and Laboratory Science in Medicine, National Yang-Ming University, Taipei, Taiwan; AIDS Prevention and Research Center, National Yang-Ming University, Taipei, Taiwan. Electronic address: jchuang2@ym.edu.tw.
Kaohsiung Medical University · TWInstitute of Biomedical Sciences, Academia Sinica · TWDevelopment Center for Biotechnology · TWKaohsiung Municipal Ta-Tung Hospital · TWNational Yang Ming Chiao Tung University · TWNational Yang Ming Chiao Tung University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The severe acute respiratory syndrome coronavirus (SARS-CoV) still carries the potential for reemergence, therefore efforts are being made to create a vaccine as a prophylactic strategy for control and prevention. Antibody-dependent enhancement (ADE) is a mechanism through which dengue viruses, feline coronaviruses, and HIV viruses take advantage of anti-viral humoral immune responses to infect host target cells. Here we describe our observations of SARS-CoV using ADE to enhance the infectivity of a HL-CZ human promonocyte cell line. Quantitative-PCR and immunofluorescence staining results indicate that SARS-CoV is capable of replication in HL-CZ cells, and of displaying virus-induced cytopathic effects and increased levels of TNF-α, IL-4 and IL-6 two days post-infection. According to flow cytometry data, the HL-CZ cells also expressed angiotensin converting enzyme 2 (ACE2, a SARS-CoV receptor) and higher levels of the FcγRII receptor. We found that higher concentrations of anti-sera against SARS-CoV neutralized SARS-CoV infection, while highly diluted anti-sera significantly increased SARS-CoV infection and induced higher levels of apoptosis. Results from infectivity assays indicate that SARS-CoV ADE is primarily mediated by diluted antibodies against envelope spike proteins rather than nucleocapsid proteins. We also generated monoclonal antibodies against SARS-CoV spike proteins and observed that most of them promoted SARS-CoV infection. Combined, our results suggest that antibodies against SARS-CoV spike proteins may trigger ADE effects. The data raise new questions regarding a potential SARS-CoV vaccine, while shedding light on mechanisms involved in SARS pathogenesis.

Indexed as

Angiotensin-Converting Enzyme 2AnimalsAntibodies, ViralCell LineChlorocebus aethiopsCoronavirus Nucleocapsid ProteinsCytopathogenic Effect, ViralHumansNucleocapsid ProteinsPeptidyl-Dipeptidase AReceptors, IgGReceptors, VirusSevere Acute Respiratory SyndromeSevere acute respiratory syndrome-related coronavirusSpike Glycoprotein, CoronavirusVero CellsACE2 protein, humanAngiotensin-Converting Enzyme 2Antibodies, ViralCoronavirus Nucleocapsid ProteinsNucleocapsid ProteinsPeptidyl-Dipeptidase AReceptors, IgGReceptors, VirusSpike Glycoprotein, CoronavirusViral VaccinesAntibody-dependent enhancementAnti-spike antibodyFc receptorsHL-CZSARS-CoV

Identifiers

PMID25073113
PMCPMC7092860
OpenAlexW2028352585

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.